|
|
|||||||||
Clinical Investigations |
1 Positron Medical Center, Hamamatsu Medical Center, Hamakita, Japan
2 Central Research Laboratory, Hamamatsu Photonics K.K., Hamakita, Japan
3 Department of Gynecology, Hamamatsu Medical Center, Hamamatsu, Japan
This study was designed to compare the value of PET using 11C-choline with that of PET using 18F-FDG for the diagnosis of gynecologic tumors. Methods: We examined 21 patients, including 18 patients with untreated primary tumors and 3 patients with suspected recurrence of ovarian cancer. 11C-choline PET and 18F-FDG PET were performed within 2 wk of each other on each patient. The patients fasted for at least 5 h before the PET examinations, and PET was performed 5 min (11C-choline) and 60 min (18F-FDG) after injection of each tracer. PET images were corrected for the transmission data, and the reconstructed images were visually analyzed. Then, the standardized uptake value (SUV) was calculated for quantitative assessment of tumor uptake. PET results were compared with surgical histology or >6 mo of clinical observations. Results: Of 18 untreated patients, 11C-choline PET correctly detected primary tumors in 16 patients, whereas 18F-FDG PET detected them in 14 patients. In 1 patient with small uterine cervical cancer and 1 diabetic patient with uterine corpus cancer, only 11C-choline PET was true-positive. Both tracers were false-negative for atypical hyperplasia of the endometrium in 1 patient and were false-positive for pelvic inflammatory disease in 1 patient. For the diagnosis of recurrent ovarian cancer (n = 3), 11C-choline PET and 18F-FDG PET were true-positive in 1 patient, whereas neither tracer could detect cystic recurrent tumor and microscopic peritoneal disease in the other 2 patients. In the 15 patients with true-positive results for both tracers, tumor SUVs were significantly higher for 18F-FDG than for 11C-choline (9.14 ± 3.78 vs. 4.61 ± 1.61, P < 0.0001). In 2 patients with uterine cervical cancer, parailiac lymph node metastases were clearly visible on 18F-FDG PET but were obscured by physiologic bowel uptake on 11C-choline PET. Conclusion: The use of 11C-choline PET is feasible for imaging of gynecologic tumors. Unlike 18F-FDG PET, interpretation of the primary tumor on 11C-choline PET is not hampered by urinary radioactivity; however, variable background activity in the intestine may interfere with the interpretation.
Key Words: 11C-choline PET 18F-FDG PET gynecologic tumors diagnosis
This article has been cited by other articles:
![]() |
C. von Forstner, J.-H. Egberts, O. Ammerpohl, D. Niedzielska, R. Buchert, P. Mikecz, U. Schumacher, K. Peldschus, G. Adam, C. Pilarsky, et al. Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer J. Nucl. Med., August 1, 2008; 49(8): 1362 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamamoto, Y. Nishiyama, R. Kameyama, K. Okano, H. Kashiwagi, A. Deguchi, M. Kaji, and M. Ohkawa Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET J. Nucl. Med., August 1, 2008; 49(8): 1245 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Terauchi, U. Tateishi, T. Maeda, D. Kanou, H. Daisaki, Y. Moriya, N. Moriyama, and T. Kakizoe A Case of Colon Cancer Detected by Carbon-11 Choline Positron Emission Tomography/Computed Tomography: An Initial Report Jpn. J. Clin. Oncol., October 1, 2007; 37(10): 797 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. van Waarde, P. L. Jager, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Comparison of Sigma-Ligands and Metabolic PET Tracers for Differentiating Tumor from Inflammation J. Nucl. Med., January 1, 2006; 47(1): 150 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pandit-Taskar Oncologic Imaging in Gynecologic Malignancies J. Nucl. Med., November 1, 2005; 46(11): 1842 - 1850. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canevari, et al. Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression Cancer Res., October 15, 2005; 65(20): 9369 - 9376. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Schmid, H. John, R. Zweifel, T. Cservenyak, G. Westera, G. W. Goerres, G. K. von Schulthess, and T. F. Hany Fluorocholine PET/CT in Patients with Prostate Cancer: Initial Experience Radiology, May 1, 2005; 235(2): 623 - 628. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |